{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T11:54:07Z","timestamp":1780055647980,"version":"3.54.0"},"reference-count":37,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,11,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 has transformed the natural history of relapsed and refractory B-cell acute lymphoblastic leukemia and aggressive B-cell non-Hodgkin lymphoma. Based on these results, CD19 CAR T cells have since been tested in largely incurable lymphomas, including mantle cell lymphoma, follicular lymphoma, and marginal zone lymphoma, with promising early results that raise the question of whether this cellular immunotherapy could have curative potential and change the natural history of these diseases. This article reviews these results and this hypothesis.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020003391","type":"journal-article","created":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T20:47:05Z","timestamp":1607028425000},"page":"5858-5862","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":17,"title":["C(h)AR-ting a new course in incurable lymphomas: CAR T cells for mantle cell and follicular lymphomas"],"prefix":"10.1182","volume":"4","author":[{"given":"Caron A.","family":"Jacobson","sequence":"first","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7578-0393","authenticated-orcid":false,"given":"Marcela V.","family":"Maus","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,11,24]]},"reference":[{"issue":"16","key":"2020120315410841400_B1","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study [published correction appears in Blood. 2018;131(5):587-588]","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"11","key":"2020120315410841400_B2","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1056\/NEJMc1800913","article-title":"CAR T-cell therapy in large B-cell lymphoma","volume":"378","author":"Neelapu","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"2020120315410841400_B3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"2020120315410841400_B4","author":"Abramson","year":"2019"},{"issue":"10254","key":"2020120315410841400_B5","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"2020120315410841400_B6","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1038\/s41467-018-05395-y","article-title":"The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity","volume":"9","author":"Helsen","year":"2018","journal-title":"Nat Commun"},{"issue":"1","key":"2020120315410841400_B7","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1038\/s41467-019-10097-0","article-title":"Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response","volume":"10","author":"Baeuerle","year":"2019","journal-title":"Nat Commun"},{"issue":"1","key":"2020120315410841400_B8","doi-asserted-by":"crossref","first-page":"1785608","DOI":"10.1080\/2162402X.2020.1785608","article-title":"Versatile chimeric antigen receptor platform for controllable and combinatorial T cell therapy","volume":"9","author":"Feldmann","year":"2020","journal-title":"OncoImmunology"},{"issue":"14","key":"2020120315410841400_B9","first-page":"1632","article-title":"Optimized tandem CD19\/CD20 CAR-engineered T cells in refractory\/relapsed B-cell lymphoma","volume":"136","author":"Tong","year":"2020","journal-title":"Blood"},{"issue":"10","key":"2020120315410841400_B10","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","article-title":"Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial","volume":"26","author":"Shah","year":"2020","journal-title":"Nat Med"},{"issue":"1","key":"2020120315410841400_B11","doi-asserted-by":"crossref","first-page":"10541","DOI":"10.1038\/s41598-017-10940-8","article-title":"Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment","volume":"7","author":"Yeku","year":"2017","journal-title":"Sci Rep"},{"issue":"6","key":"2020120315410841400_B12","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"issue":"14","key":"2020120315410841400_B13","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"2020120315410841400_B14","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","article-title":"Postibrutinib outcomes in patients with mantle cell lymphoma","volume":"127","author":"Martin","year":"2016","journal-title":"Blood"},{"issue":"15","key":"2020120315410841400_B15","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"issue":"9","key":"2020120315410841400_B16","doi-asserted-by":"crossref","first-page":"E966","DOI":"10.1073\/pnas.1500712112","article-title":"Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK","volume":"112","author":"Sagiv-Barfi","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"2020120315410841400_B17","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"},{"issue":"11","key":"2020120315410841400_B18","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-15-1527","article-title":"The addition of the BTK inhibitor ibrutinib to anti-CD19 chimeric antigen receptor T cells (CART19) improves responses against mantle cell lymphoma","volume":"22","author":"Ruella","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2020120315410841400_B19","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/leu.2016.262","article-title":"Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms","volume":"31","author":"Ruella","year":"2017","journal-title":"Leukemia"},{"issue":"8","key":"2020120315410841400_B20","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1172\/JCI89756","article-title":"Ibrutinib treatment improves T cell number and function in CLL patients","volume":"127","author":"Long","year":"2017","journal-title":"J Clin Invest"},{"issue":"26","key":"2020120315410841400_B21","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9","key":"2020120315410841400_B22","doi-asserted-by":"crossref","first-page":"e122627","DOI":"10.1172\/jci.insight.122627","article-title":"Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed\/refractory CLL","volume":"5","author":"Geyer","year":"2019","journal-title":"JCI Insight"},{"issue":"15","key":"2020120315410841400_B23","article-title":"Interim analysis of ZUMA-5: a phase II study of axicabtagene ciloleucel (axi-cel) in patients with relapsed\/refractory indolent non-Hodgkin lymphoma [abstract]","volume":"38","author":"Jacobson","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020120315410841400_B24","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol"},{"issue":"26","key":"2020120315410841400_B25","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"2020120315410841400_B26","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1182\/blood.2019000905","article-title":"High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy","volume":"134","author":"Hirayama","year":"2019","journal-title":"Blood"},{"issue":"2","key":"2020120315410841400_B27","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1084\/jem.167.2.582","article-title":"Single cell origin of bigenotypic and biphenotypic B cell proliferations in human follicular lymphomas","volume":"167","author":"Cleary","year":"1988","journal-title":"J Exp Med"},{"issue":"3","key":"2020120315410841400_B28","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.scr.2010.07.003","article-title":"Prospective isolation of clonogenic mantle cell lymphoma-initiating cells","volume":"5","author":"Chen","year":"2010","journal-title":"Stem Cell Res (Amst)"},{"issue":"6B","key":"2020120315410841400_B29","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1111\/j.1582-4934.2009.00865.x","article-title":"Side population of a murine mantle cell lymphoma model contains tumour-initiating cells responsible for lymphoma maintenance and dissemination","volume":"14","author":"Vega","year":"2010","journal-title":"J Cell Mol Med"},{"issue":"12","key":"2020120315410841400_B30","doi-asserted-by":"crossref","first-page":"4708","DOI":"10.1182\/blood.V91.12.4708","article-title":"Follicular lymphomas contain a clonally linked but phenotypically distinct neoplastic B-cell population in the interfollicular zone","volume":"91","author":"Dogan","year":"1998","journal-title":"Blood"},{"issue":"12","key":"2020120315410841400_B31","doi-asserted-by":"crossref","first-page":"e134612","DOI":"10.1172\/jci.insight.134612","article-title":"Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy","volume":"5","author":"Chen","year":"2020","journal-title":"JCI Insight"},{"issue":"8","key":"2020120315410841400_B32","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo [published correction appears in Mol Ther. 2015;23(7):1278]","volume":"17","author":"Milone","year":"2009","journal-title":"Mol Ther"},{"issue":"9","key":"2020120315410841400_B33","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0813101106","article-title":"Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains","volume":"106","author":"Carpenito","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"issue":"303","key":"2020120315410841400_B34","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"issue":"625","key":"2020120315410841400_B35","doi-asserted-by":"crossref","first-page":"eaay8248","DOI":"10.1126\/scisignal.aay8248","article-title":"4-1BB costimulation promotes CAR T cell survival through noncanonical NF-\u03baB signaling","volume":"13","author":"Philipson","year":"2020","journal-title":"Sci Signal"},{"key":"2020120315410841400_B36","article-title":"A distinct transcriptional program in human CAR T cells bearing the 4-1BB signaling domain revealed by scRNA-seq [published online ahead of print 25 July 2020]","author":"Boroughs","journal-title":"Mol Ther"},{"issue":"6","key":"2020120315410841400_B37","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1172\/JCI133215","article-title":"Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor durability","volume":"130","author":"Guedan","year":"2020","journal-title":"J Clin Invest"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/22\/5858\/1790771\/advancesadv2020003391c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/22\/5858\/1790771\/advancesadv2020003391c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T20:47:21Z","timestamp":1607028441000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/22\/5858\/474239\/ChARting-a-new-course-in-incurable-lymphomas-CAR-T"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,24]]},"references-count":37,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2020,11,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020003391","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,24]]}}}